James Hoppe, MD
Family Medicine · South Plainfield, NJNPI 1174587661
Payments from drug & device makers
Across 419 payments — averaging $15.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- AbbVie$1K
- Lilly USA, LLC$535
- Novo Nordisk$497
- Bayer$366
- Exact Sciences$313
- plus $2K from 22 others
What the payments were for
- Food & beverage$6,32399%
- Education$471%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 96 | $1,789 |
| AbbVie(2 entities) | 91 | $1,067 |
| Lilly USA, LLC | 40 | $535 |
| Novo Nordisk | 31 | $497 |
| Bayer | 18 | $366 |
| Exact Sciences | 16 | $313 |
| Merck | 22 | $305 |
| Johnson & Johnson | 16 | $225 |
| Kowa Pharmaceuticals America, Inc. | 13 | $175 |
| Boehringer Ingelheim | 12 | $167 |
| Hologic Sales And Service, LLC | 7 | $136 |
| Pfizer | 8 | $116 |
| Avion Pharmaceuticals | 6 | $80 |
| Amarin Pharma, Inc. | 5 | $72 |
| Abbott | 4 | $71 |
| Antares Pharma, Inc. | 4 | $63 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $52 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $47 |
| Myovant Sciences Inc. | 3 | $46 |
| Impel Pharmaceuticals Inc. | 3 | $46 |
| GSK | 3 | $42 |
| Phadia US Inc. | 2 | $35 |
| Corcept Therapeutics | 2 | $34 |
| Agile Therapeutics, Inc. | 2 | $29 |
| Clarus Therapeutics Inc. | 2 | $20 |
| Lupin Inc. | 1 | $15 |
| Biohaven Pharmaceuticals, Inc. | 1 | $14 |
| Amgen | 1 | $13 |
How this compares
$6,370 in reported general payments places this provider in the 90th percentile of 2,084 family medicine providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 48 | $94,648 |
| FarxigaDapagliflozin Propanediol | 77 | $83,338 |
| JanuviaSitagliptin Phosphate | 49 | $70,772 |
| MounjaroTirzepatide | 41 | $55,849 |
| TrulicityDulaglutide | 32 | $51,440 |
| JanumetSitagliptin Phos/Metformin Hcl | 41 | $41,038 |
| JardianceEmpagliflozin | 22 | $33,796 |
| Xigduo XrDapaglifloz Propaned/Metformin | 29 | $32,472 |
| RybelsusSemaglutide | 18 | $26,319 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 21 | $11,751 |
| Incruse ElliptaUmeclidinium Bromide | 16 | $10,884 |
| Olmesartan Medoxomil | 284 | $7,073 |
| Atorvastatin Calcium | 431 | $4,416 |
| Olmesartan-HydrochlorothiazideOlmesartan/Hydrochlorothiazide | 111 | $4,408 |
| Metoprolol Succinate | 226 | $3,507 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| MerckJanuvia, Janumet, Janumet Xr | $305 | $123,560111 claims |
| Novo NordiskOzempic, Rybelsus | $497 | $120,96866 claims |
| Lilly USA, LLCMounjaro, Trulicity | $535 | $107,28973 claims |
| AstraZenecaFarxiga, Symbicort | $1,789 | $86,69791 claims |
| Boehringer IngelheimJardiance | $167 | $33,79622 claims |
| GSKIncruse Ellipta | $42 | $10,88416 claims |
| AbbVieSynthroid | $1,067 | $1,59326 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,084 family medicine providers in New Jersey.
Other family medicine in South Plainfield
- Howard HassmanClementon$47.1M
- Matthew HongNorth Cape May$15.3M
- Rubaba HussainClark$3.8M
- Gaurang BrahmbhattHoboken$2.6M
- Michael DobrowClifton$2.1M
- Mikhail VarshavskiChatham$1.4M
- Amit BhalodiaCamden$707K
- Jennifer AmicoNew Brunswick$627K
- Janet ColeFar Hills$466K
- Matthew PintoMarlton$239K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.